Our results led to the hypothesis that pioglitazone may have no beneficial impact on tau-mediated neuroinflammation, possibly explaining the failure of this treatment strategy in clinical trials of Alzheimer’s disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.